UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2014
File No. 000-54598
Stellar Biotechnologies Inc.
(Name of Registrant)
332 E. Scott Street, Port Hueneme, CA 93041
(Address of Principal executive offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
SIGNATURE
Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Stellar Biotechnologies, Inc.
(Registrant)
| Dated: 8/28/14 | By: /s/ Kathi Niffenegger |
|
Kathi Niffenegger
|
|
|
Chief Financial Officer
|
Exhibits:
99.1 Notice of Change of Financial Year-End
Exhibit 99.1
NOTICE OF CHANGE OF FINANCIAL YEAR-END
August 28, 2014
British Columbia Securities Commission
Alberta Securities Commission
Dear Sirs
| Re: | Stellar Biotechnologies, Inc. (the “Company”) |
| Notice Pursuant to Section 4.8 of National Instrument 51-102 |
Pursuant to Section 4.8 of National Instrument 51-102 Continuous Disclosure Obligations, the Company wishes to advise that it is changing its financial year-end from August 31 to September 30.
Reason for the Change
Fiscal year and quarterly filings to coincide with calendar quarters.
Relevant Dates for Financial Reporting Periods
The old financial year-end of the Company was August 31.
The new financial year-end of the Company will be September 30.
The transition year of the Company will be the one month ended September 30, 2014.
The length, ending dates and filing deadlines of the periods, including the comparative periods, of the annual financial statements to be filed for the Company’s transition year and its new financial year are as follows:
|
Transition Year
|
Comparative Annual Financial Statements to Transition Year
|
Filing Deadline for Annual Statements for Transition Year
|
New Financial Year
|
Comparative Annual Financial Statements to New Financial Year
|
Canadian Filing Deadline for Annual Financial Statements for New Financial Year
|
US Filing Deadline for Annual Financial Statements for New Financial Year
|
|
One month ended September 30, 2014
|
Filed with New Financial Year
|
Filed with New Financial Year
|
Twelve months ended September 30, 2015
|
One month ended September 30, 2014 and twelve months ended August 31, 2014
|
January 28, 2016
|
December 14, 2015
|
The length, ending dates and filing deadlines of the periods, including the comparative periods, of the interim financial statements to be filed for the Company’s transition year and its new financial year are as follows:
|
Interim Periods for Transition Year
|
Comparative Interim Periods to Interim Periods in Transition Year
|
Filing Deadline for Interim Financial Statements of Transition Year
|
Interim Periods for New Financial Year
|
Comparative Interim Periods in New Financial Year
|
Canadian Filing Deadline for Interim Financial Statements of New Financial Year
|
US Filing Deadline for Interim Financial Statements of New Financial Year
|
|
N/A
|
N/A
|
N/A
|
Three months ended December 31, 2014
|
Three months ended December 31, 2013
|
March 2, 2015
|
February 9, 2015
|
|
Three and six months ended March 31, 2015
|
Three and six months ended March 31, 2014
|
June 1, 2015
|
May 10, 2015
|
|||
|
Three and nine months ended June 30, 2015
|
Three and nine months ended June 30, 2014
|
August 31, 2015
|
August 9, 2015
|
DATED at Port Hueneme, California, this 28th date of August, 2014.
STELLAR BIOTECHNOLOGIES, INC.
Per: /s/ Kathi Niffenegger
__________________________________________________
Kathi Niffenegger
Chief Financial Officer